Tag: diseases

People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more...

Adults with type 2 diabetes on semaglutide 1 mg whose dose was increased to 2 mg were as likely to reach an HbA1c level...

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978

Ractigen Therapeutics Announces ADA 2026 Late-Breaking Presentation Highlighting saRNA as a New Frontier in Obesity Control

Breakthrough preclinical data demonstrate that LiCO-saUcp1 effectively turns white fat into calorie-burning brown fat, driving massive fat loss while fully preserving lean muscle mass...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use

Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate

AMB-702 demonstrates superior target coverage and efficacy in lean non-human primates The dataset was shared as part of a poster presentation at the American Diabetes...

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Oban BioPharma Announces Presentation of Late-Breaking Abstract at ADA 2026 Highlighting OBT-676: A First-in-Class Small Molecule Combining Dual Amylin and Calcitonin Receptor Full Agonism...

STAMFORD, Conn., June 05, 2026 (GLOBE NEWSWIRE) -- Oban BioPharma today announced that preclinical data for OBT-676, a lead small-molecule candidate for the treatment of obesity and type 2 diabetes, has been selected for a late-breaking presentation at the upcoming American Diabetes Association (ADA) 86th Scientific Sessions being held from June 5^th-8^th in New Orleans, LA. The study characterizes OBT-676 as a new molecular entity that achieves potent full agonism at the amylin and calcitonin receptors (DACRA) while simultaneously delivering partial agonism across the GLP-1, GIP, and glucagon (Triple-G) pathways. OBT-676 demonstrated significant reduction in food intake and adipose-selective weight loss in the industry-standard rat diet-induced obesity (DIO) model.

Novo Nordisk’s investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes–presented at ADA 2026

A phase 2 study of investigational once-weekly subcutaneous zenagamtide showed statistically significant reductions in blood sugar in adults with type 2 diabetes compared to...

The Canadian Food Inspection Agency implements disease control measures to prevent spread of New World Screwworm

OTTAWA, ON, June 5, 2026 /CNW/ - Following a confirmed finding of New World screwworm in a calf in Texas, the Canadian Food Inspection...

Food Safety Testing Market Expected to Reach $44.1 Billion by 2033, at a CAGR of 7% : Allied Market Research

Driven by intensifying food safety requirements with the increased stringency of regulatory guidelines, a substantial and growing incidence of food fraud across global supply...

Food Safety Testing Market Expected to Reach $44.1 Billion by 2033, at a CAGR of 7% : Allied Market Research

Driven by intensifying food safety requirements with the increased stringency of regulatory guidelines, a substantial and growing incidence of food fraud across global supply...

Canadian Food Inspection Agency testing shows strong food safety in Canada

OTTAWA, ON, June 5, 2026 /CNW/ - The Canadian Food Inspection Agency (CFIA), Canada's largest science-based regulator, has published annual national testing and monitoring...

Brayton Purcell LLP Highlights KQED Reporting on Federal Bill Affecting Artificial Stone Silicosis Claims

NOVATO, Calif., June 5, 2026 /PRNewswire/ -- Brayton Purcell LLP is bringing attention to a June 4, 2026 article by KQED News journalist Farida Jhabvala...

Altesa BioSciences Presents New Phase 2 Vapendavir Challenge Study Results at 2026 American Society for Microbiology (ASM) Microbe Conference

New clinical findings further reinforce therapeutic potential of vapendavir as targeted approach to preventing rhinovirus-driven COPD exacerbationsWASHINGTON, June 5, 2026 /PRNewswire/ -- Altesa BioSciences, a...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsDiseases

Clinical Amino Acid Profiles Anchor PureHealth Research’s New Natural Peptides Supplements

SKG Launches PS700 Neck Massager, Bringing Deep Kneading, Layered Heat, and Immersive Audio to Everyday Recovery

All In FutureTech Alliance Provides Strategic Updates: Hainan AIFA Digital Industrial Park, Silicon Photonics Compute Center Planning, and Cross-Border Optical Network Integration

Tag: diseases

People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more...

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Ractigen Therapeutics Announces ADA 2026 Late-Breaking Presentation Highlighting saRNA as a New Frontier in Obesity Control

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with...

Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Oban BioPharma Announces Presentation of Late-Breaking Abstract at ADA 2026 Highlighting OBT-676: A First-in-Class Small Molecule Combining Dual Amylin and Calcitonin Receptor Full Agonism...

Novo Nordisk’s investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes–presented at ADA 2026

The Canadian Food Inspection Agency implements disease control measures to prevent spread of New World Screwworm

Food Safety Testing Market Expected to Reach $44.1 Billion by 2033, at a CAGR of 7% : Allied Market Research

Food Safety Testing Market Expected to Reach $44.1 Billion by 2033, at a CAGR of 7% : Allied Market Research

Canadian Food Inspection Agency testing shows strong food safety in Canada

Brayton Purcell LLP Highlights KQED Reporting on Federal Bill Affecting Artificial Stone Silicosis Claims

Altesa BioSciences Presents New Phase 2 Vapendavir Challenge Study Results at 2026 American Society for Microbiology (ASM) Microbe Conference

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us